Zenas Q3 Loss Widens to $108.9M as R&D and Milestone Costs Jump; $647.1M Cash Funds Runway Into 2029
ZBIO has more than doubled off its 52-week low of $13.5.
Summary
Zenas' Q3 10-Q shows the net loss widening to $108.9 million on higher R&D and milestone payments, offset by $647.1 million in cash that management says funds operations into 2029 ahead of the May 2027 obexelimab PDUFA date.
Key Events · Earnings and Guidance · ZBIO
-
Q3 Net Loss Widens to $108.9M
Net loss was $108.9 million, or $1.65 per share, versus $51.5 million a year earlier; nine-month net loss reached $301.4 million.
-
R&D and Milestone Costs Drive Burn
R&D rose $24.1 million to $58.5 million, including $12.9 million of orelabrutinib trial costs, and acquired IPR&D was $27.5 million from the $25.0 million InnoCare Near-Term Milestone plus a $2.5 million Xencor milestone.
-
$647.1M Cash, Runway Into 2029
Cash, cash equivalents and investments were $647.1 million at September 30, 2026; management projects funding into 2029, or through Q2 2029 assuming the $75 million Royalty Pharma milestone and $75 million Pharmakon draw.
-
Leverage Now Material
Long-term liabilities total $398.9 million, including $223.2 million carrying value of 2.50% convertible notes (conversion price $26.50) and $76.1 million on the senior secured term loan, plus a $99.2 million royalty obligation at a 32.2% effective rate.
Analysis · ZBIO · Life Sciences
The headline numbers were already out this morning, but the 10-Q is where the real detail sits: the quarterly loss more than doubled to $108.9 million from $51.5 million, driven by a $24.1 million jump in R&D (mostly orelabrutinib trial costs) and $27.5 million of acquired IPR&D from the InnoCare and Xencor milestones. Against that burn, $647.1 million of cash and investments plus the potential $75 million Royalty Pharma milestone and $75 million Pharmakon draw are projected to carry the company into 2029 — and the obexelimab PDUFA date of May 27, 2027 is the binary event that decides whether that runway is enough. The balance sheet is now levered: $230 million of 2.50% convertible notes (conversion price $26.50) and a $75 million drawn term loan sit alongside a $99.2 million royalty obligation carrying a 32.2% effective rate.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZBIO was trading at $28.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $13.50 to $44.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.